The pharmacologic management of premenstrual dysphoric disorder.

The pharmacologic management of premenstrual dysphoric disorder. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

The pharmacologic management of premenstrual dysphoric disorder. Abstract Text:

Andrea J Rapkin,Sharon A Winer,Andrea J Rapkin,Sharon A Winer,

Premenstrual dysphoric disorder (PMDD) is characterized by physical, affective and behavioral symptoms that are linked to the luteal phase of the menstrual cycle and relieved soon after the onset of menses. The disorder is chronic and exerts a major impact on personal relationships and occupational productivity for the estimated 6% of reproductive-aged women who fulfill strict PMDD criteria and the almost 20% of women who nearly meet these criteria. There are now various pharmacologic options that have demonstrated efficacy for PMDD and two of these approaches have an approved indication for treatment from the US FDA: three selective serotonin re-uptake inhibitors; and for women who also desire hormonal contraception, a low dose oral contraceptive pill containing the progestin drospirenone, in a new dosing regimen. Due to the unique pathophysiology of the disorder, the selective serotonin re-uptake inhibitors can be effectively administered intermittently, with dosing limited to the luteal phase of the cycle (2 weeks prior to menses). In the future, new pharmacotherapy will likely evolve from research evaluating other hormonal formulations that inhibit ovulation, without simulating PMDD-like symptoms, or novel pharmacologic agents that modulate the central neurotransmission.

The pharmacologic management of premenstrual dysphoric disorder. Publishing Authors By Initials

AJ Rapkin,SA Winer,AJ Rapkin,SA Winer,

For similar abstracts research abstracts see: abstracts research

PUBMED ID PMID:

MEDLINE DATE:

The pharmacologic management of premenstrual dysphoric disorder. Journal Published:

PUBLICATION TYPE: Journal Article

Journal: Expert opinion on pharmacotherapy

VOLUME: 9

Page Numbers: 429-45

Journal Abbreviation:

ISSN: 1744-7666

DAY: 28

MONTH: Feb

YEAR: 2008

The pharmacologic management of premenstrual dysphoric disorder. Information

Number of References:

LANGUAGE: eng

NlmUniqueID: 100897346

The pharmacologic management of premenstrual dysphoric disorder. Keywords Mesh Terms:

KEYWORDS:

MESH TERMS:

Chemical & Substance for Abstract: The pharmacologic management of premenstrual dysphoric disorder. Information

Substance Name:

Registry Number:

Grant and Affiliation Information for The pharmacologic management of premenstrual dysphoric disorder.

AFFILIATION: Department of Obstetrics & Gynecology, David Geffen School of Medicine at UCLA, 10833 Le Conte Avenue, Los Angeles, California 90095-1740, USA. arapkin@mednet.ucla.edu

Country: England

AGENCY:

GRANT:

ACRONYM:

MEDLINETA: Expert Opin Pharmacother

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

The pharmacologic management of premenstrual dysphoric disorder Related Publications

• A framework for interactive examination of automatic segmented tumors in a virtual environment.
• A simple approach to quality assurance in a complex ambulatory care setting.
• Advances in adjuvant endocrine therapy for postmenopausal women.
• Age of menopause among women who remain premenopausal following treatment for early breast cancer: long-term results from International Breast Cancer Study Group Trials V and VI.
• Auditory cortex mapmaking: principles, projections, and plasticity.
• Branched projections in the auditory thalamocortical and corticocortical systems.
• Commoner skin diseases of the external genitalia.
• Concurrent tonotopic processing streams in auditory cortex.
• Connections of cat auditory cortex: I. Thalamocortical system.
• Connections of cat auditory cortex: II. Commissural system.
• Connections of cat auditory cortex: III. Corticocortical system.
• Cutaneous leishmaniasis; report of a case and summary of the newer concepts.
• Drospirenone/ethinyl estradiol.
• Elastic fibers in unusual dermatoses.
• Follow-up care of patients with breast cancer.
• Herpes zoster and malignancy.
• Heterogeneity of breast cancer and implications of adjuvant chemotherapy.
• How does infiltration behavior modify the composition of ambient PM2.5 in indoor spaces? An analysis of RIOPA data.
• Impact of a mixed strength and endurance exercise intervention on insulin levels in breast cancer survivors.
• Long-term psychosocial adjustment of older vs younger survivors of breast and endometrial cancer.
• Optimizing endocrine therapy for estrogen receptor-positive breast cancer: treating the right patients for the right length of time.
• Phase II trial of lapatinib for brain metastases in patients with human epidermal growth factor receptor 2-positive breast cancer.
• Preoperative therapy in invasive breast cancer: pathologic assessment and systemic therapy issues in operable disease.
• Preoperative therapy in invasive breast cancer: reviewing the state of the science and exploring new research directions.
• Racial Differences in Clinical Outcomes From Metastatic Breast Cancer: A Pooled Analysis of CALGB 9342 and 9840--Cancer and Leukemia Group B.
• Risk perceptions and psychosocial outcomes of women with ductal carcinoma in situ: longitudinal results from a cohort study.
• Sarcoidosis mimicking metastatic breast cancer.
• The pharmacologic management of premenstrual dysphoric disorder.
• Uterine inversion associated with bicornuate uterus.
• Vascular compliance in the cardiometabolic syndrome.